APR 2 1 2004 PRADE APPRICATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Igor l	D. Polyakov) Art Unit:	1645
-------------------------	-------------	-------------	------

U.S. Appln. No. : 10/085,703) Examiner: Minnifield, Nita M.

Confirmation No.: 2400

U.S. Filing Date : February 28,2002

Title of Invention: Dermatomycosis Vaccine

Attny. Docket No.: 3/400-4-C4

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

April 21, 2004

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

hereinbelow.
1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

	1.97(d). This Statement is being filed after the period specified in 37 C.F.R. c) but on or before payment of the issue fee. This Statement is accompanied by a ent as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. p).
	1.97(e).
	Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
	No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in secti	1.704(d). Each item of information contained in the accompanying information ture statement was cited in a communication from a foreign patent office in a rpart application, which communication was not received by any individual designated ion 1.56(c) more than thirty (30) days prior to the filing of the accompanying ation disclosure statement.
	The Commissioner is hereby authorized to charge payment of any additional filing quired under 37 C.F.R. §1.16 and any patent application processing fees under 37 §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Mary Ellen M. Devlin Attorney for Applicant(s)

Reg. No. 27,928

Patent Department .
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4868

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as express mail #EV 376716315 in an envelope addressed to:

y-Eller M. Devlin, Reg. No. 27,928

Certificate of Mailing

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on April 21, 2004.

3 of 3

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/085,703

Filing Date February 28, 2002

First Named Inventor Igor Dimitriesich Polyakov

Art Unit 1645

Examiner Name Minnifield, Nita M.

Complete if Known

(Use as many sheets as necessary)

Sheet 1 of 7 Attorney Docket Number 3/400-4-C4

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (if known)} US- 4,129,647	12/12/1978	Edmund Klein	· · · · · · · · · · · · · · · · · · ·
		US-4,229,434	10/21/1980	Arutjun, K. et al	*
		US- 4,657,761	04/21/1987	Cesar M. Pinto	
***************************************		^{US-} 4,368,191	1/11/1983	Sarkisov et al	
		^{US-} 5,277,904	1/11/1994	Pier, A	
** ha ex < p** ************* a te : E4.6 *******************		US- 5,284,652	2/8/1994	Pier	
		^{US-} 6,428,789	8/6/2002	Stobel et al	
		^{US-} 6,132,733	10/17/2000	Werner et al	
		^{US-} 5,453,273	9/26/1995	Werner et al	
		^{US-} 6,290,950	9/18/2001	Poliakov et al	
		US-			
		US-			
MATERIA (1900 MATERIA (1900 MATERIA)		US-	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	·	
Mr. og granjianskisk (1881 og agrangskiskisk (1882 og		US-			
************************		US-			
	ļ	US-			
]	US-			
		03-			

		FOREIG	N PATENT DOC	JIVIENIS	T	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
		EP 0393371	10/24/1990	Jefferson Labs, Inc.		
		WO 9307894	4/29/1993	BI Vetmedica GmbH		
					,	
						L
	T					

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Tris collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Supplificate for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 7

	Complete if Known	
Application Number	10/085,703	
Filing Date	February 28, 2002	
First Named Inventor	Igor Dimitriesich Polyakov	
Art Unit	1645	
Examiner Name	Minnifield, Nita M.	
Attorney Docket Number	3/400-4-C4	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
		A.J. Chanis, Dissertation, J.R. Kovalenko Institute, Moskow (February 27, 1989) E.L. Kenney and M. Huppert., "Immunization Against Superficial Fungous Infection", J. Invest. Derm., 32, pp. 7-13 (1959) ("Chanis")			
		E.L. Kenney and M. Huppert., "Immunization Against Superficial Fungous Infection", J. Invest. Derm., 32, pp. 7-13 (1959)			
		K. Wawrzkiewicz and J. Wawrzkiewicz, "Early Immunization of Calves with an Inactivated Vaccine Against Trichophytosis", Polskie Archiwum Weterynaryjne, 28, p.p. 5-16 (1988)			
		K. Wawrzkiewicz and J. Wawrzkiewicz, "Effect of Levamisole on the Immune Response of Guinea Pigs Immunized with Inactivated Trichophyton verrucosum Strain", Annales UMCS (Lublin), section DD, 39, pp. 53-63 (1984)			
		P. Kielstein and W. Richter, "Versuche zur Immunprophylaxe der Rindertrichophytie", Sonderdruck aus dem Archiv fur Experimentelle Veterinarmedizin Bd. 24, H. 5/1970, pp. 1205-1218 (1970) ("Kielstein")			
		E. Florian et al., "Aktiv Immunizalasi Kiserletek Borjak Tarlosomore Ellen", Magyar Allatorvosok Lapja, 19(12), pp. 529-530 (1964) ("Florian")			
		M.L. Wharton et al., "Active immunization Against Trichophyton Purpureum Infection in Rabbits", J. Invest. Dermatol. 14, pp. 291-303 (1950)			
		C. Mosher et al., "Ringworm (Microsporum canis) with Inactivated Fungal Vaccine", Vet Med/Small Animal Clin., 72, pp. 1343-1345 (1977)			
		E. Ibragimov et al., "Investigation of the immunogenic and curative features of a formaldehyde vaccine against ringworm in cattle", Usbek Veterinary Research Institute XXX Part 1 Taskent (USSR) (1980) ("Ibragimov")			
		K. Wawrzkiewicz et al.,., "Szczepionka Inaktywowana w Profilaktyce i Leczeniu Grzybicy Skornej Bydla", Medycyna Weterynaryjna, 44(11), pp. 648-651 (1988) ("Wawrzkiewics-Medycyna")			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF Comments of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7

Substitute forform 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

3

Sheet

	Complete if Known)
Application Number	10/085,703	
Filing Date	February 28, 2002	
First Named Inventor	Igor Dimitriesich Polyakov	
Art Unit	1645	
Examiner Name	Minnifield, Nita M.	
Attorney Docket Number	3/400-4-C4	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		CAB International Abstract No. &92290473 (1989) ("CAB Abstract")			
		T. Kocik, "Proba Oceny Wartosci Immunogennych Szczepionek Zywych i Zabitych Przeciwko Trychofitozie Dla Swinek Morskich I Mlodego Bydla", Polskie Archivum Weterynarynje, 23(3), pp. 95-107 (1982)			
		Anon, "Results of a Therapeutic Efficacy Test Using an Inactivated Microsporum Canis Vaccine", typewritten material 5-εε available at US Dept. of Agriculture, National Agricultual Library (19εε)			
	•••••	R. Weiss et al., "Immunisierungsversuche an Meerschweinchen mit einem Trichophyton Verrucosum-Lebendantigen", Mykosen, 20 (2), pp. 54-64 (1977)			
	•••••	A.K. Sarkisov et al., Biological Abstracts, Vol. ε1, Abstract No. 4165 (19ε6) **			
		W. Wawrzkiewicz et al., Biological Abstracts, Vol. 92, Abstract No. 124650 (1991)**			
		A.K. Sarkisov et al., "Specific Prophylaxis of Trichophytosis in Animals", Mikol. Fitophatol., 19(1), pp. 51-57 (1985)**			
		W. Wawrzkiewicz et al., "An Inactivated Vaccine Against Ringworm", Comp. Immu. Microbiol. Infect. Dis., 15(1), pp. 31-40 (1992)**			
		C.L. Mosher et al., "Treatment of Ringworm (Microsporum canis) with Inactivated Fungal Vaccine", Vet. Med., pp. 1343-45 (August 1977)**			
	••••••	R. Gudding et al., "Vaccination of Cattle Against Ringworm Caused by Trichophyton verrucosum", Am. J. Vet. Res., 47(11), pp. 2415-17 (1986)**			

	1		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Unget the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRANSUBStitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7

	Complete if Known	`
Application Number	10/085/703	
Filing Date	February 28, 2002	
First Named Inventor	Igor Dimitriesich Polyakov	
Art Unit	1645	
Examiner Name	Minnifield, Nita M.	
Attorney Docket Number	3/400-4-C4	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Polyakov et al., "Clinical Manifestations of Dermatomycosis induced", Byulleten Vsesoyuznogo Instituta Experimental noi Vet., 65, pp. 43-45 (1988)**	
	•••••	Sarkisov et al., "Dermatomycosis of Camels and Biological Properties of the Causal Agent", Veterinariya (Moskva), 10, pp. 31-35 (1989)**	
	•••••••••••	lvanova et al., "Trichophyton sarkisovii New Species, A New Pathogenic", "Mikol. Fitopatol., 17(5), pp. 363-67 (1983)**	
•••••	••••••	Segal, "Immunization Against Fungal Diseases in Man and Animal" in Handbook of Applied Mycology, Vol. 2, pp. 341-68 (1991)**	
		Grappel et al., "Immunology of Dermatophytes and Dermatophytosis", Bacteriological Riev., 38(2), pp. 222-250 (1974)**	
		A.C. PIER ET AL; Experimental immunity to Microsporum canis and cross reactions with other dermatophytes of veterinary importance; Journal of Medicine and Veterinary Mycology; (1995) Vol. 33 pages 93-97	
	······	ROAR GUDDING ET AL; Immunoprophylaxis of bovine dermatophytosis; Can Vet J; Vol. 36 pages 302-306 (May 1995)	
		J.K. WABACHA ET AL; Occurrence of dermatophytosis (ringworm) due to Trichophyton verrucosum in dairy calves and its spread to animal attendants; JI S. Afr. vet. Ass. (1998) Vol. 69 No. 4 pages 172-173	
		M. PAVLAS ET AL; The Therapeutic and Preventive Effectiveness of Vaccine Against Trichophytosis in Cattle; Research Institute of Veterinary Medicine (1979) Vol. 24 No. 4 pages 209-215	
		J. WAWRZKIEWICZ ET AL; Monovalent and Combined Inactivated Killed Vaccines in the Prophylaxis of Trichophytosis of Breeding Foxes; Med Weter (1991) Vol 47 No. 7 pages 317-320	

		r	T	
	F	Dota .		ı
	Examiner	Date	<u> </u>	i
ı	Signature	Considered		,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Eperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

5

7

Application Number	10/085,703	
Filing Date	February 28, 2002	
First Named Inventor	Igor Dimitriesich Polyakov et al	
Art Unit	1645	•
Examiner Name	Minnifield, Nita M.	
Attorney Docket Number	3/400-4-04	

Complete if Known

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		DOUPARINOVA, M. ET AL; Epidemiological aspects of ringworm in calves on large farms; Central Vet. Res. Inst. (1978) Vol. 15 No. 1 pages 74-77	
	•••••••	GOLOVINA, N.P. ET AL; Pathogenicity and immunogenicity of strains of Trichophyton verrucosum from different sources; Byulleten Vsesoyuznogo Inst. (1982) Vol. 45 pages 59-61	•••••
		KAMIONOWSKI, M. ET AL; Efficacy of Alpevac (Biowet Pulawy) in the prevention of dermatomycosis in rabbits; Zycie Weterynaryjne (2001) Vol. 76 No. 2 pages 101-102 Issn: 0137-6810	***********
		WOLOSZYN, S. ET AL; Efficacy of Vaccines in the control of dermatomycoses in rabbits; Medycyna Weterynaryjna (1996) Vol. 52 No. 8 pages 518-521 ISSN: 0025-8628	
	••••••••••	BALABANOFF V.A.; Occupational dermatomycoses of zoophilic origin in Bulgarial; Dermatosen in Burf und Umwelt (1985) Vol 33 No. 5 pages 170-174	
	••••••	WOLOSZYN, S. ET AL; Prevalence and specific prevention against trichophytosis in breeding foxes; Med Weter (1983) Vol. 39 No. 7 pages 387-391	
		O. AAMONDT ET AL; Vaccination of Norwegian Cattle against Ringworm; Vet. Med B (1982) Vol. 29 pages 451-456 ISSN: 0721-1856	
	••••••	EIVIND LIVEN ET AL; Efficacy of vaccination against ringworm in cattle; Nord Vet. Med. (1985) Vol. 37 page 187	
		KOMAREK, J. ET AL; Ringworm of cattle results of vaccination; Veterinarniho Ustavu (1982) No. 12 pages 69-74	
	•	J.M.B. SMITH ET AL; Strategies for the development of a vaccine against ringworm; Journal of Medical and Veterinary Mycology (1995) Vol. 33 pages 87-91	

$\overline{}$	 1	
Examiner	Date	
Signature	Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pagework Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/085,703 Filing Date INFORMATION DISCLOSURE February 28, 2002 First Named Inventor STATEMENT BY APPLICANT lgor Dimitriesich Polyakov Art Unit 1645 (Use as many sheets as necessary) Examiner Name Minnifield, Nita M. Attorney Docket Number Sheet 7 3/400-4-C4 6

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		A. RYBNIKAR ET AL; Vaccination of Horses Against Trichophytosis; ACTA Vet Brno (1991) Vol. 60 pages 165-169	
		A. RYBNIKAR ET AL; Immunity in cattle vaccinated against ringworm; Mycoses (1991) Vol. 34 pages 433-436	
		J.M. MCGREGOR ET AL; Possible mechanisms of immune modulation in chronic dermatophytoses: an in votro study; British Journal of Dermatology (1992) Vol. 127 pages 233-238	
		P.J. GORDON ET AL; Efficacy of a live attenuated Trichophyton verrucosum vaccine for control of bovine dermatophytosis; Veterinary Record (1996) Vol. 139 Pages 395-396	
		A. KH. SARKISOV ET AL; Modern Methods for Control of Animal Dermatomycosis; Advance in Agriultural Science (1987) pages 181-197	
		A. TAGER ET AL; Immunotherapy of Superficial Dermatomycoses; Dermatologica (1973) Vol. 147 pages 123-129	
		P. KIELSTEIN; Sustematic control of dermatophytosis profunda of cattle in the former GDR; Mycoses (1990) Vol. 33 pages 575-579	
		D.J. DEBOER ET AL; In vestigations of a killed dermatophyte cell-wall vaccine against infection with Microsporum canis in cats; Research in Vet Sci. (1995) Vol. 59 No. 2 pages 110-113	
		KAREN A. MORIELLO ET AL; Feline Dermatophytosis; Feline Dermatology (1995) Vol. 25 No. 4 pages 901-921	
:		PERSPECTIVES ON CATS; When the Fungus (Ringworm) Is Among Us; The Cornell Feline Health Center (1994) pages 1-3 and 8	

	<u> </u>	1
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Utilice; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Utilice; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498/PTO Complete if Known Application Number 10/085,703 Filing Date INFORMATION DISCLOSURE February 28, 2002 First Named Inventor STATEMENT BY APPLICANT Igor Dimitriesich Polyakov Art Unit 1645 (Use as many sheets as necessary) Examiner Name Minnifield, Nita M. Attorney Docket Number 3/400-4-C4 Sheet 7

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
•		STANISLAW; Med. Weterynaryjna (1987) Vol. 43 pages 259-64	
•••••••••••			
		·	İ
••••••••••			
			1
		·	
	ļ		
			上
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.